Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)

Amid aproci­ten­tan’s reg­u­la­to­ry re­view, Idor­sia is buy­ing back the hy­per­ten­sion drug from J&J in $350M deal

John­son & John­son’s Janssen is hand­ing back the glob­al de­vel­op­ment and com­mer­cial­iza­tion rights to the hy­per­ten­sion can­di­date aproci­ten­tan to Idor­sia. This new agree­ment ef­fec­tive­ly un­does a deal from 2017, when J&J paid Idor­sia $230 mil­lion for com­mer­cial­iza­tion rights for the as­set.

Idor­sia is set to pay J&J 306 mil­lion Swiss francs ($343.9 mil­lion) pend­ing rev­enues. J&J would be en­ti­tled to re­ceive 30% of any out-li­cens­ing or di­vest­ment deals spe­cif­ic to aproci­ten­tan, as well as 10% of a sep­a­rate deal re­lat­ed to an Idor­sia as­set once aproci­ten­tan has re­ceived a reg­u­la­to­ry nod. J&J would al­so be en­ti­tled to low- to mid-sin­gle dig­it roy­al­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.